Chicago Business

Chicago Business

AbbVie buys Celsius Therapeutics for $250 million

AbbVie buys Celsius Therapeutics for 0 million

Having trouble viewing this email? See the online version

Health Pulse Breaking News

Thursday, June 27, 2024

Sign outside of AbbVie's North Chicago headquarters

AbbVie buys drug developer Celsius Therapeutics for $250 million

AbbVie is counting on the Cambridge-based biotech to further beef up its arsenal of drugs to fight Crohn's disease and ulcerative colitis.

Did someone forward this to you? Sign up for Health Pulse breaking news alerts here and unlock access to the full story with a Health Pulse subscription.

UNLOCK YOUR ACCESS

Discover the latest insights, analysis & opinion needed to navigate Chicago's complex business landscape.

<![if !mso]> <![endif]>

VIEW OUR SUBSCRIPTION OFFERS

This email was sent to chicagobusinessus627@emails.newslettersbase.com
Manage My Account | Contact Us

© 2024 Crain Communications Inc
130 E. Randolph St., Suite 3200, Chicago, IL 60601 United States
Privacy Policy | Terms and Conditions | Unsubscribe

This email was sent

June 27, 2024 4:06pm
Country:

United States
Tags